Topics
Glioblastoma | Prognosis | Overall Survival
Home > Publications > Topics > Glioblastoma > Prognosis > Overall Survival
Gendreau
J, Mehkri Y, Kuo C, Chakravarti S, Jimenez MA, Shalom M, Kazemi F,
Mukherjee D.
Clinical
Predictors of Overall Survival in Very Elderly Patients With
Glioblastoma: A National Cancer Database Multivariable Analysis.
Neurosurgery.
2024 Jun 28. doi:
10.1227/neu.0000000000003072. PMID:
38940573. Observational study˰ ˍ
Habibi MA, Ghorbani M, Esmaeilian S, Tajvidi F, Nekutalaban P,
Boskabadi AR, Alemi F, Zafari R, Mirjani MS, Eazi S, Minaee P.
Stereotactic radiosurgery versus
combined stereotactic radiosurgery and bevacizumab for recurrent
glioblastoma; a systematic review and meta-analysis of survival.
Neurosurg
Rev. 2024 Jul 13;47(1):323. doi:
10.1007/s10143-024-02585-9. PMID:
39002028. Review; Meta-analysis˰
ˍ
*Harter PN, Weber KJ, Ricklefs FL, Drexler R, Schüller U,
Hack M, Hanke T, Dohmen H, Acker T, von Deimling A, Hasselblatt M,
Divé I, Unger K, Steinbach JP, Capper D, Ronellenfitsch MW.
Survival probability of epigenetically
defined IDH-wild-type glioblastoma without necrosis or vascular
proliferation.
Neurooncol
Adv. 2024 Aug 2;6(1):vdae138. doi:
10.1093/noajnl/vdae138. PMID:
39184173. Observational study. ˍ
Snider S, De Domenico P, Roncelli F, Bisoglio A, Braga M, Ghelfi
A, Barzaghi LR, Mura C, Mortini P, Gagliardi F.
Pre-operative
mean platelet volume is associated with overall survival in
patients with IDH-wildtype glioblastoma undergoing maximal safe
resection.
Oncol
Lett. 2024 Sep 30;28(6):576. doi:
10.3892/ol.2024.14709. PMID:
39397801. Observational study. ˍ
Alirezaei Z, Amouheidari A, BasirianJahromi R, Seyyedhosseini S,
Hamidi A.
Survival Analysis of
Glioblastoma: A Scientometric Perspective.
World
Neurosurg. 2024 Nov 20:S1878-8750(24)01919-3? doi:
10.1016/j.wneu.2024.11.059? PMID:
39577630. Bibliometric analysis˰
ˍ
Ohba S, Teranishi T, Matsumura K, Kumon M, Kojima D, Fujiwara E,
Nakao K, Kuwahara K, Murayama K, Pareira ES, Yamada S, Joko M,
Nakae S, Muto J, Nishiyama Y, Adachi K, Sasaki H, Abe M, Hasegawa
M, Hirose Y.
Factors involved in
maintaining Karnofsky Performance Status (≥ 50%) in
glioblastoma, IDH-wildtype patients treated with temozolomide and
radiotherapy.
Sci
Rep. 2025 Jan 11;15(1):1750. doi:
10.1038/s41598-025-85339-x. PMID:
39799218. Observational study. ˍ
Maragno E, Ricchizzi S, Winter NR, Hellwig SJ, Stummer W, Hahn T,
Holling M.
Predictive modeling with
linear machine learning can estimate glioblastoma survival in
months based solely on MGMT-methylation status, age and sex.
Acta
Neurochir (Wien). 2025 Feb 24;167(1):52. doi:
10.1007/s00701-025-06441-7. PMID:
39992425. Observational study. ˍ
Demetz M, Hecker C, Salim HA, Krigers A, Steinbacher J, Machegger
L, Kerschbaumer J, Buchta M, Pöppe J, Geiger P, Spinello A,
Kraus TFJ, Griessenauer CJ, Thomé C, Freyschlag CF,
Schwartz C.
Epilepsy as primary tumor
manifestation correlates with patient status, age, and tumor
volume but not with survival in elderly glioblastoma patients: a
retrospective bicentric analysis.
Neurosurg
Rev. 2025 Feb 24;48(1):264. doi:
10.1007/s10143-025-03397-1. PMID:
39994084. Observational study. ˍ
Leppert J, Ditz C, Matschke J, Krenzlin H, Keric N, Ziemann C,
Hahn L, Matone MV, Liubich L, Streubel K, Schacht H, Hillbricht C,
Kuppler P, Rades D, Löser A.
Sex-related
Survival Differences in Patients With Glioblastoma - Results From
a Retrospective Analysis.
Anticancer
Res. 2025 Apr 28;45(5):2059-2069. doi:
10.21873/anticanres.17580. PMID:
40295065. Observational
study. ˍ
*van Dijck JTJM, Ardon H, Balvers RK, Bos EM, Bosscher L, Brouwers
HB, Ho VKY, Hovinga K, Kwee L, Ter Laan M, Nabuurs RJA, Robe PAJT,
van Geest S, van der Veer O, Verburg N, Wagemakers M, de Witt
Hamer PC, Rodriguez Girondo M, Nandoe Tewarie RDS; Quality
Registry Neuro Surgery glioblastoma working group from the Dutch
Society of Neurosurgery.
Survival
prediction in glioblastoma: 10-year follow-up from the Dutch
Neurosurgery Quality Registry.
J
Neurooncol. 2025 May 23. doi:
10.1007/s11060-025-05080-3. PMID:
40410639. Observational study. ˍ
Aman R, Desbassarie F, Lubis AR, Ardiansyah IR.
Prognostic
factors and survival of recurrent glioblastoma: a systematic
review.
Folia
Med (Plovdiv). 2025 Jun 6;67(3). doi:
10.3897/folmed.67.e142227. PMID:
40524591. Review. ˍ
She L, Wu H, Zhang X, Zheng C, Su L.
A
retrospective analysis of survival prognostic factors and risk
stratification in recurrent glioblastoma.
Ann
Med. 2025 Sep 24;57(1):2533435. doi:
10.1080/07853890.2025.2533435. PMID:
40991008. Observational study. ˍ
Bessette J, Arditi J, Noreck J, Edwards R, Kaiserman J, Wortelboer
R, Nguyen MA, Siwik W, Gautam S, Szymanski T, Wong ET.
Medical
comorbidities prognosticate survival in glioblastoma.
BJC
Rep. 2025 Oct 24;3(1):75. doi:
10.1038/s44276-025-00189-4. PMID:
41136649. Observational study. ˍ
Basaran AE, Wellkisch AC, Güresir E, Wach J.
Extent
of reoperation predicts survival in recurrent IDH-wildtype
glioblastoma based on institutional data and individual patient
data meta analysis.
Discov
Oncol. 2025 Nov 13;16(1):2099. doi:
10.1007/s12672-025-03928-8. PMID:
41231323. Meta analysis. ˍ